Celgosivir

• CAT Number: I000790
• CAS Number: 121104-96-9
• Molecular Formula: C12H21NO5
• Molecular Weight: 259.3
• Purity: ≥95%
• Target: alpha-glucosidase I
• Solubility: soluble in DMSO
• Storage: Store at -20°C
• IC50: 16 and 47 umol/L ( Using plaque assay and a cytopathic assay )[2]
• IUPAC Name: [(1S,6S,7S,8R,8aR)-1,7,8-trihydroxy-1,2,3,5,6,7,8,8a-octahydroindolizin-6-yl] butanoate
• InChI: InChI=1S/C12H21NO5/c1-2-3-9(15)18-8-6-13-5-4-7(14)10(13)12(17)11(8)16/h7-8,10-12,14,16-17H,2-6H2,1H3/t7-,8-,10+,11+,12+/m1/s1
• InChIKey: HTJGLYIJVSDQAE-PPJKGSGRSA-N
• SMILES: CCCC(O[C@@H]1CN2CC[C@@H](O)[C@@]2([H])[C@H](O)[C@H]1O)=O

Celgosivir (Cat.No:I000790) is a small molecule antiviral drug that has been developed for the treatment of viral infections such as dengue fever and hepatitis C. It works by inhibiting the activity of a host enzyme called alpha-glucosidase, which is required for the replication of these viruses. Celgosivir has shown promising results in preclinical studies and clinical trials, and further research is ongoing to evaluate its efficacy and safety in treating these viral infections.

Reference

1:Extended Evaluation of Virological, Immunological and Pharmacokinetic Endpoints of CELADEN: A Randomized, Placebo-Controlled Trial of Celgosivir in Dengue Fever Patients. Sung C, Wei Y, Watanabe S, Lee HS, Khoo YM, Fan L, Rathore AP, Chan KW, Choy MM, Kamaraj US, Sessions OM, Aw P, de Sessions PF, Lee B, Connolly JE, Hibberd ML, Vijaykrishna D, Wijaya L, Ooi EE, Low JG, Vasudevan SG.PLoS Negl Trop Dis. 2016 Aug 10;10(8):e0004851. doi: 10.1371/journal.pntd.0004851. eCollection 2016 Aug. PMID: 27509020 Free PMC Article2:Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2: The search for a window for potential therapeutic efficacy. Watanabe S, Chan KW, Dow G, Ooi EE, Low JG, Vasudevan SG.Antiviral Res. 2016 Mar;127:10-9. doi: 10.1016/j.antiviral.2015.12.008. Epub 2016 Jan 13. PMID: 26794905 3:Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial. Low JG, Sung C, Wijaya L, Wei Y, Rathore AP, Watanabe S, Tan BH, Toh L, Chua LT, Hou Y, Chow A, Howe S, Chan WK, Tan KH, Chung JS, Cherng BP, Lye DC, Tambayah PA, Ng LC, Connolly J, Hibberd ML, Leo YS, Cheung YB, Ooi EE, Vasudevan SG.Lancet Infect Dis. 2014 Aug;14(8):706-15. doi: 10.1016/S1473-3099(14)70730-3. Epub 2014 May 28. PMID: 24877997 4:Dose- and schedule-dependent protective efficacy of celgosivir in a lethal mouse model for dengue virus infection informs dosing regimen for a proof of concept clinical trial. Watanabe S, Rathore AP, Sung C, Lu F, Khoo YM, Connolly J, Low J, Ooi EE, Lee HS, Vasudevan SG.Antiviral Res. 2012 Oct;96(1):32-5. doi: 10.1016/j.antiviral.2012.07.008. Epub 2012 Jul 31. PMID: 22867971 5:Celgosivir treatment misfolds dengue virus NS1 protein, induces cellular pro-survival genes and protects against lethal challenge mouse model. Rathore AP, Paradkar PN, Watanabe S, Tan KH, Sung C, Connolly JE, Low J, Ooi EE, Vasudevan SG.Antiviral Res. 2011 Dec;92(3):453-60. doi: 10.1016/j.antiviral.2011.10.002. Epub 2011 Oct 12. PMID: 22020302 6:Celgosivir, an alpha-glucosidase I inhibitor for the potential treatment of HCV infection. Durantel D.Curr Opin Investig Drugs. 2009 Aug;10(8):860-70. Review. PMID: 19649930 7:Action of celgosivir (6 O-butanoyl castanospermine) against the pestivirus BVDV: implications for the treatment of hepatitis C. Whitby K, Taylor D, Patel D, Ahmed P, Tyms AS.Antivir Chem Chemother. 2004 May;15(3):141-51. PMID: 15266896